Literature DB >> 9167773

Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research.

A Pousette1, K Carlström, P Henriksson, M Grande, R Stege.   

Abstract

BACKGROUND: In order to develop a hormone-resistant analog to the hormone sensitive cell-line LNCaP, different methods were tried.
METHODS: After almost one year of continuous culture in RPMI-1640, containing a low concentration of androgens, the hormone sensitive cell-line LNCaP became hormone resistant and was named LNCaP-r.
RESULTS: We used the LNCaP/LNCaP-r model system in order to study methods for the parenteral treatment of prostate carcinoma with estrogens, to study the mechanism of action of estramustine, and to identify markers useful as predictive tests for prostate carcinoma.
CONCLUSIONS: A model system made up of the hormone sensitive prostate LNCaP cell-line and the hormone resistant LNCaP-r subline was developed and characterized. This system is, despite a number of limitations, easy to use as a first step to test different hypotheses that can be studied further in later clinical trials.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9167773     DOI: 10.1002/(sici)1097-0045(19970515)31:3<198::aid-pros9>3.0.co;2-h

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells.

Authors:  V Sydorenko; Y Shuba; S Thebault; M Roudbaraki; G Lepage; N Prevarskaya; R Skryma
Journal:  J Physiol       Date:  2003-05-01       Impact factor: 5.182

2.  Modulation of rotation-induced lift force for cell filtration in a low aspect ratio microchannel.

Authors:  Jian Zhou; Premkumar Vummidi Giridhar; Susan Kasper; Ian Papautsky
Journal:  Biomicrofluidics       Date:  2014-07-30       Impact factor: 2.800

3.  Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Authors:  A P Stubbs; P D Abel; M Golding; G Bhangal; Q Wang; J Waxman; G W Stamp; E N Lalani
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

4.  A new human prostate carcinoma cell line, 22Rv1.

Authors:  R M Sramkoski; T G Pretlow; J M Giaconia; T P Pretlow; S Schwartz; M S Sy; S R Marengo; J S Rhim; D Zhang; J W Jacobberger
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

5.  Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.

Authors:  D N Grigoryev; B J Long; I P Nnane; V C Njar; Y Liu; A M Brodie
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

6.  Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy.

Authors:  Björn Johansson; Mohammad R Pourian; Yin-Choy Chuan; Irene Byman; Anders Bergh; See-Tong Pang; Gunnar Norstedt; Tomas Bergman; Ake Pousette
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

7.  Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.

Authors:  Y Kawano; S Diez; P Uysal-Onganer; R S Darrington; J Waxman; R M Kypta
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

8.  A novel approach to identify driver genes involved in androgen-independent prostate cancer.

Authors:  Ellyn N Schinke; Victor Bii; Arun Nalla; Dustin T Rae; Laura Tedrick; Gary G Meadows; Grant D Trobridge
Journal:  Mol Cancer       Date:  2014-05-23       Impact factor: 27.401

9.  Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.

Authors:  Victor M Bii; Casey P Collins; Jonah D Hocum; Grant D Trobridge
Journal:  Oncotarget       Date:  2018-02-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.